In March 2025, the company announced new strategies for the direct-to-consumer offering of its Wegovy weight loss drug. The company set up a whole new pharmacy, termed NovoCare, which might cost buyers $499 per 30 days for usage of the drug, lower than half the price of the drug as a result of other pharmaceutical distribution networks.[fifty three